Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

A recombinant antibody against Plasmodium vivax UIS4 for distinguishing replicating from dormant liver stages.

Schafer C, Dambrauskas N, Steel RW, Carbonetti S, Chuenchob V, Flannery EL, Vigdorovich V, Oliver BG, Roobsoong W, Maher SP, Kyle D, Sattabongkot J, Kappe SHI, Mikolajczak SA, Sather DN.

Malar J. 2018 Oct 17;17(1):370. doi: 10.1186/s12936-018-2519-7.

2.

Characterization of Plasmodium vivax Proteins in Plasma-Derived Exosomes From Malaria-Infected Liver-Chimeric Humanized Mice.

Gualdrón-López M, Flannery EL, Kangwanrangsan N, Chuenchob V, Fernandez-Orth D, Segui-Barber J, Royo F, Falcón-Pérez JM, Fernandez-Becerra C, Lacerda MVG, Kappe SHI, Sattabongkot J, Gonzalez JR, Mikolajczak SA, Del Portillo HA.

Front Microbiol. 2018 Jun 25;9:1271. doi: 10.3389/fmicb.2018.01271. eCollection 2018.

3.

Author Correction: A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum.

Roth A, Maher SP, Conway AJ, Ubalee R, Chaumeau V, Andolina C, Kaba SA, Vantaux A, Bakowski MA, Thomson-Luque R, Adapa SR, Singh N, Barnes SJ, Cooper CA, Rouillier M, McNamara CW, Mikolajczak SA, Sather N, Witkowski B, Campo B, Kappe SHI, Lanar DE, Nosten F, Davidson S, Jiang RHY, Kyle DE, Adams JH.

Nat Commun. 2018 Jun 8;9(1):2317. doi: 10.1038/s41467-018-04817-1.

4.

A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum.

Roth A, Maher SP, Conway AJ, Ubalee R, Chaumeau V, Andolina C, Kaba SA, Vantaux A, Bakowski MA, Luque RT, Adapa SR, Singh N, Barnes SJ, Cooper CA, Rouillier M, McNamara CW, Mikolajczak SA, Sather N, Witkowski B, Campo B, Kappe SHI, Lanar DE, Nosten F, Davidson S, Jiang RHY, Kyle DE, Adams JH.

Nat Commun. 2018 May 9;9(1):1837. doi: 10.1038/s41467-018-04221-9. Erratum in: Nat Commun. 2018 Jun 8;9(1):2317.

5.

Plasmodium falciparum Liver Stage Infection and Transition to Stable Blood Stage Infection in Liver-Humanized and Blood-Humanized FRGN KO Mice Enables Testing of Blood Stage Inhibitory Antibodies (Reticulocyte-Binding Protein Homolog 5) In Vivo.

Foquet L, Schafer C, Minkah NK, Alanine DGW, Flannery EL, Steel RWJ, Sack BK, Camargo N, Fishbaugher M, Betz W, Nguyen T, Billman ZP, Wilson EM, Bial J, Murphy SC, Draper SJ, Mikolajczak SA, Kappe SHI.

Front Immunol. 2018 Mar 14;9:524. doi: 10.3389/fimmu.2018.00524. eCollection 2018.

6.

In Vitro Culture, Drug Sensitivity, and Transcriptome of Plasmodium Vivax Hypnozoites.

Gural N, Mancio-Silva L, Miller AB, Galstian A, Butty VL, Levine SS, Patrapuvich R, Desai SP, Mikolajczak SA, Kappe SHI, Fleming HE, March S, Sattabongkot J, Bhatia SN.

Cell Host Microbe. 2018 Mar 14;23(3):395-406.e4. doi: 10.1016/j.chom.2018.01.002. Epub 2018 Feb 22.

PMID:
29478773
7.

Assessing drug efficacy against Plasmodium falciparum liver stages in vivo.

Flannery EL, Foquet L, Chuenchob V, Fishbaugher M, Billman Z, Navarro MJ, Betz W, Olsen TM, Lee J, Camargo N, Nguyen T, Schafer C, Sack BK, Wilson EM, Saunders J, Bial J, Campo B, Charman SA, Murphy SC, Phillips MA, Kappe SH, Mikolajczak SA.

JCI Insight. 2018 Jan 11;3(1). pii: 92587. doi: 10.1172/jci.insight.92587. [Epub ahead of print]

8.

Humoral protection against mosquito bite-transmitted Plasmodium falciparum infection in humanized mice.

Sack BK, Mikolajczak SA, Fishbaugher M, Vaughan AM, Flannery EL, Nguyen T, Betz W, Jane Navarro M, Foquet L, Steel RWJ, Billman ZP, Murphy SC, Hoffman SL, Chakravarty S, Sim BKL, Behet M, Reuling IJ, Walk J, Scholzen A, Sauerwein RW, Ishizuka AS, Flynn B, Seder RA, Kappe SHI.

NPJ Vaccines. 2017 Oct 9;2:27. doi: 10.1038/s41541-017-0028-2. eCollection 2017.

9.

Proteogenomic analysis of the total and surface-exposed proteomes of Plasmodium vivax salivary gland sporozoites.

Swearingen KE, Lindner SE, Flannery EL, Vaughan AM, Morrison RD, Patrapuvich R, Koepfli C, Muller I, Jex A, Moritz RL, Kappe SHI, Sattabongkot J, Mikolajczak SA.

PLoS Negl Trop Dis. 2017 Jul 31;11(7):e0005791. doi: 10.1371/journal.pntd.0005791. eCollection 2017 Jul.

10.

Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects.

Kublin JG, Mikolajczak SA, Sack BK, Fishbaugher ME, Seilie A, Shelton L, VonGoedert T, Firat M, Magee S, Fritzen E, Betz W, Kain HS, Dankwa DA, Steel RW, Vaughan AM, Noah Sather D, Murphy SC, Kappe SH.

Sci Transl Med. 2017 Jan 4;9(371). pii: eaad9099. doi: 10.1126/scitranslmed.aad9099.

PMID:
28053159
11.

Corrigendum: Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.

Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, Enama ME, Gordon IJ, Chang LJ, Sarwar UN, Zephir KL, Holman LA, James ER, Billingsley PF, Gunasekera A, Chakravarty S, Manoj A, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, K C N, Murshedkar T, DeCederfelt H, Plummer SH, Hendel CS, Novik L, Costner PJ, Saunders JG, Laurens MB, Plowe CV, Flynn B, Whalen WR, Todd JP, Noor J, Rao S, Sierra-Davidson K, Lynn GM, Epstein JE, Kemp MA, Fahle GA, Mikolajczak SA, Fishbaugher M, Sack BK, Kappe SH, Davidson SA, Garver LS, Björkström NK, Nason MC, Graham BS, Roederer M, Sim BK, Hoffman SL, Ledgerwood JE, Seder RA; VRC 312 and VRC 314 Study Teams.

Nat Med. 2016 Jun 7;22(6):692. doi: 10.1038/nm0616-692c. No abstract available.

PMID:
27270781
12.

Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.

Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, Enama ME, Gordon IJ, Chang LJ, Sarwar UN, Zephir KL, Holman LA, James ER, Billingsley PF, Gunasekera A, Chakravarty S, Manoj A, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, K C N, Murshedkar T, DeCederfelt H, Plummer SH, Hendel CS, Novik L, Costner PJ, Saunders JG, Laurens MB, Plowe CV, Flynn B, Whalen WR, Todd JP, Noor J, Rao S, Sierra-Davidson K, Lynn GM, Epstein JE, Kemp MA, Fahle GA, Mikolajczak SA, Fishbaugher M, Sack BK, Kappe SH, Davidson SA, Garver LS, Björkström NK, Nason MC, Graham BS, Roederer M, Sim BK, Hoffman SL, Ledgerwood JE, Seder RA.

Nat Med. 2016 Jun;22(6):614-23. doi: 10.1038/nm.4110. Epub 2016 May 9. Erratum in: Nat Med. 2016 Jun 7;22(6):692.

PMID:
27158907
13.

Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice.

Mikolajczak SA, Vaughan AM, Kangwanrangsan N, Roobsoong W, Fishbaugher M, Yimamnuaychok N, Rezakhani N, Lakshmanan V, Singh N, Kaushansky A, Camargo N, Baldwin M, Lindner SE, Adams JH, Sattabongkot J, Kappe SH.

Cell Host Microbe. 2015 Apr 8;17(4):526-35. doi: 10.1016/j.chom.2015.02.011. Epub 2015 Mar 19.

14.

Cyclic GMP balance is critical for malaria parasite transmission from the mosquito to the mammalian host.

Lakshmanan V, Fishbaugher ME, Morrison B, Baldwin M, Macarulay M, Vaughan AM, Mikolajczak SA, Kappe SH.

MBio. 2015 Mar 17;6(2):e02330. doi: 10.1128/mBio.02330-14.

15.

Host-based Prophylaxis Successfully Targets Liver Stage Malaria Parasites.

Douglass AN, Kain HS, Abdullahi M, Arang N, Austin LS, Mikolajczak SA, Billman ZP, Hume JCC, Murphy SC, Kappe SHI, Kaushansky A.

Mol Ther. 2015 May;23(5):857-865. doi: 10.1038/mt.2015.18. Epub 2015 Feb 4.

16.

Susceptibility to Plasmodium yoelii preerythrocytic infection in BALB/c substrains is determined at the point of hepatocyte invasion.

Kaushansky A, Austin LS, Mikolajczak SA, Lo FY, Miller JL, Douglass AN, Arang N, Vaughan AM, Gardner MJ, Kappe SH.

Infect Immun. 2015 Jan;83(1):39-47. doi: 10.1128/IAI.02230-14. Epub 2014 Oct 13.

17.

A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion.

Mikolajczak SA, Lakshmanan V, Fishbaugher M, Camargo N, Harupa A, Kaushansky A, Douglass AN, Baldwin M, Healer J, O'Neill M, Phuong T, Cowman A, Kappe SH.

Mol Ther. 2014 Sep;22(9):1707-15. doi: 10.1038/mt.2014.85. Epub 2014 May 14.

18.

Of men in mice: the success and promise of humanized mouse models for human malaria parasite infections.

Kaushansky A, Mikolajczak SA, Vignali M, Kappe SH.

Cell Microbiol. 2014 May;16(5):602-11. doi: 10.1111/cmi.12277. Epub 2014 Mar 6. Review.

19.

First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers.

Spring M, Murphy J, Nielsen R, Dowler M, Bennett JW, Zarling S, Williams J, de la Vega P, Ware L, Komisar J, Polhemus M, Richie TL, Epstein J, Tamminga C, Chuang I, Richie N, O'Neil M, Heppner DG, Healer J, O'Neill M, Smithers H, Finney OC, Mikolajczak SA, Wang R, Cowman A, Ockenhouse C, Krzych U, Kappe SH.

Vaccine. 2013 Oct 9;31(43):4975-83. doi: 10.1016/j.vaccine.2013.08.007. Epub 2013 Sep 8.

PMID:
24029408
20.

Malaria parasite liver stages render host hepatocytes susceptible to mitochondria-initiated apoptosis.

Kaushansky A, Metzger PG, Douglass AN, Mikolajczak SA, Lakshmanan V, Kain HS, Kappe SH.

Cell Death Dis. 2013 Aug 8;4:e762. doi: 10.1038/cddis.2013.286.

21.

Suppression of host p53 is critical for Plasmodium liver-stage infection.

Kaushansky A, Ye AS, Austin LS, Mikolajczak SA, Vaughan AM, Camargo N, Metzger PG, Douglass AN, MacBeath G, Kappe SH.

Cell Rep. 2013 Mar 28;3(3):630-7. doi: 10.1016/j.celrep.2013.02.010. Epub 2013 Mar 7.

22.

Perturbations of Plasmodium Puf2 expression and RNA-seq of Puf2-deficient sporozoites reveal a critical role in maintaining RNA homeostasis and parasite transmissibility.

Lindner SE, Mikolajczak SA, Vaughan AM, Moon W, Joyce BR, Sullivan WJ Jr, Kappe SH.

Cell Microbiol. 2013 Jul;15(7):1266-83. doi: 10.1111/cmi.12116. Epub 2013 Feb 27.

23.

Neuroimmunological blood brain barrier opening in experimental cerebral malaria.

Nacer A, Movila A, Baer K, Mikolajczak SA, Kappe SH, Frevert U.

PLoS Pathog. 2012;8(10):e1002982. doi: 10.1371/journal.ppat.1002982. Epub 2012 Oct 25.

24.

A transgenic Plasmodium falciparum NF54 strain that expresses GFP-luciferase throughout the parasite life cycle.

Vaughan AM, Mikolajczak SA, Camargo N, Lakshmanan V, Kennedy M, Lindner SE, Miller JL, Hume JC, Kappe SH.

Mol Biochem Parasitol. 2012 Dec;186(2):143-7. doi: 10.1016/j.molbiopara.2012.10.004. Epub 2012 Oct 27.

PMID:
23107927
25.

Complete Plasmodium falciparum liver-stage development in liver-chimeric mice.

Vaughan AM, Mikolajczak SA, Wilson EM, Grompe M, Kaushansky A, Camargo N, Bial J, Ploss A, Kappe SH.

J Clin Invest. 2012 Oct;122(10):3618-28. doi: 10.1172/JCI62684. Epub 2012 Sep 10.

26.

Development of humanized mouse models to study human malaria parasite infection.

Vaughan AM, Kappe SH, Ploss A, Mikolajczak SA.

Future Microbiol. 2012 May;7(5):657-65. doi: 10.2217/fmb.12.27. Review.

27.

Genetic engineering of attenuated malaria parasites for vaccination.

Khan SM, Janse CJ, Kappe SH, Mikolajczak SA.

Curr Opin Biotechnol. 2012 Dec;23(6):908-16. doi: 10.1016/j.copbio.2012.04.003. Epub 2012 May 4. Review.

PMID:
22560204
28.

Plasmodium yoelii macrophage migration inhibitory factor is necessary for efficient liver-stage development.

Miller JL, Harupa A, Kappe SH, Mikolajczak SA.

Infect Immun. 2012 Apr;80(4):1399-407. doi: 10.1128/IAI.05861-11. Epub 2012 Jan 17.

29.

Immunology. Another shot at a malaria vaccine.

Kappe SH, Mikolajczak SA.

Science. 2011 Oct 28;334(6055):460-1. doi: 10.1126/science.1213934. No abstract available.

PMID:
22034421
30.

Disruption of the Plasmodium falciparum liver-stage antigen-1 locus causes a differentiation defect in late liver-stage parasites.

Mikolajczak SA, Sacci JB Jr, De La Vega P, Camargo N, VanBuskirk K, Krzych U, Cao J, Jacobs-Lorena M, Cowman AF, Kappe SH.

Cell Microbiol. 2011 Aug;13(8):1250-60. doi: 10.1111/j.1462-5822.2011.01617.x. Epub 2011 Jun 24.

31.

A genetically attenuated parasite vaccine does not require liver stage persistence to elicit sterile protective immunity against sporozoite-induced malaria in mice.

Mikolajczak SA, Vaughan AM, Soliman JM, Kappe SH.

J Infect Dis. 2010 Apr 15;201(8):1270-1; author reply 1271-2. doi: 10.1086/651279. No abstract available.

PMID:
20225958
32.

A dispensable Plasmodium locus for stable transgene expression.

Jacobs-Lorena VY, Mikolajczak SA, Labaied M, Vaughan AM, Kappe SH.

Mol Biochem Parasitol. 2010 May;171(1):40-4. doi: 10.1016/j.molbiopara.2009.12.009. Epub 2010 Jan 4.

33.

Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design.

VanBuskirk KM, O'Neill MT, De La Vega P, Maier AG, Krzych U, Williams J, Dowler MG, Sacci JB Jr, Kangwanrangsan N, Tsuboi T, Kneteman NM, Heppner DG Jr, Murdock BA, Mikolajczak SA, Aly AS, Cowman AF, Kappe SH.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13004-9. doi: 10.1073/pnas.0906387106. Epub 2009 Jul 22.

34.

Distinct malaria parasite sporozoites reveal transcriptional changes that cause differential tissue infection competence in the mosquito vector and mammalian host.

Mikolajczak SA, Silva-Rivera H, Peng X, Tarun AS, Camargo N, Jacobs-Lorena V, Daly TM, Bergman LW, de la Vega P, Williams J, Aly AS, Kappe SH.

Mol Cell Biol. 2008 Oct;28(20):6196-207. doi: 10.1128/MCB.00553-08. Epub 2008 Aug 18.

35.

Heme oxygenase-1 is an anti-inflammatory host factor that promotes murine plasmodium liver infection.

Epiphanio S, Mikolajczak SA, Gonçalves LA, Pamplona A, Portugal S, Albuquerque S, Goldberg M, Rebelo S, Anderson DG, Akinc A, Vornlocher HP, Kappe SH, Soares MP, Mota MM.

Cell Host Microbe. 2008 May 15;3(5):331-8. doi: 10.1016/j.chom.2008.04.003.

36.

Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection.

Aly AS, Mikolajczak SA, Rivera HS, Camargo N, Jacobs-Lorena V, Labaied M, Coppens I, Kappe SH.

Mol Microbiol. 2008 Jul;69(1):152-63. doi: 10.1111/j.1365-2958.2008.06271.x. Epub 2008 May 5.

37.

An efficient strategy for gene targeting and phenotypic assessment in the Plasmodium yoelii rodent malaria model.

Mikolajczak SA, Aly AS, Dumpit RF, Vaughan AM, Kappe SH.

Mol Biochem Parasitol. 2008 Apr;158(2):213-6. doi: 10.1016/j.molbiopara.2007.12.006. Epub 2007 Dec 15.

PMID:
18242728
38.

Preerythrocytic malaria vaccine development.

Mikolajczak SA, Aly AS, Kappe SH.

Curr Opin Infect Dis. 2007 Oct;20(5):461-6. Review. Erratum in: Curr Opin Infect Dis. 2007 Dec;20(6):656.

PMID:
17762778
39.

Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection.

Labaied M, Harupa A, Dumpit RF, Coppens I, Mikolajczak SA, Kappe SH.

Infect Immun. 2007 Aug;75(8):3758-68. Epub 2007 May 21.

40.

L-FABP is a critical host factor for successful malaria liver stage development.

Mikolajczak SA, Jacobs-Lorena V, MacKellar DC, Camargo N, Kappe SH.

Int J Parasitol. 2007 Apr;37(5):483-9. Epub 2007 Jan 14.

PMID:
17303141
41.

A clash to conquer: the malaria parasite liver infection.

Mikolajczak SA, Kappe SH.

Mol Microbiol. 2006 Dec;62(6):1499-506. Review.

42.

Rat PSP94 inhibits the growth and viability of the rat adenocarcinoma cell line PAIII in vitro.

Cadieux PA, Mikolajczak SA, Reeves J, Strathdee C, Reid G, Panchal CJ, Clarke MW.

Cancer Invest. 2006 Apr-May;24(3):246-55.

PMID:
16809150
43.

The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells.

Ma BY, Mikolajczak SA, Danesh A, Hosiawa KA, Cameron CM, Takaori-Kondo A, Uchiyama T, Kelvin DJ, Ochi A.

Blood. 2005 Sep 15;106(6):2002-10. Epub 2005 Jun 7.

44.

The modulation of CD40 ligand signaling by transmembrane CD28 splice variant in human T cells.

Mikolajczak SA, Ma BY, Yoshida T, Yoshida R, Kelvin DJ, Ochi A.

J Exp Med. 2004 Apr 5;199(7):1025-31.

45.

CD28 T cell costimulatory receptor function is negatively regulated by N-linked carbohydrates.

Ma BY, Mikolajczak SA, Yoshida T, Yoshida R, Kelvin DJ, Ochi A.

Biochem Biophys Res Commun. 2004 Apr 23;317(1):60-7.

PMID:
15047148
46.

A novel costimulatory signaling in human T lymphocytes by a splice variant of CD28.

Hanawa H, Ma Y, Mikolajczak SA, Charles ML, Yoshida T, Yoshida R, Strathdee CA, Litchfield DW, Ochi A.

Blood. 2002 Mar 15;99(6):2138-45.

Supplemental Content

Loading ...
Support Center